相关实验视频

Updated: Jul 18, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在第三阶段非小细胞肺癌中化学辐射后对杜尔瓦卢马布的现实世界分析

Beatrice T B Preti^1,2, Michael S Sanatani^1,2, Daniel Breadner^1,2

¹Schulich School of Medicine & Dentistry, Western University, London, ON N6A 3K7, Canada.

Current oncology (Toronto, Ont.)

|August 25, 2023

概括

这项现实研究发现,用于第三阶段非小细胞肺癌 (NSCLC) 的化学辐射后,辅助药杜瓦卢马布的毒性率为64.4%,包括21%的3级+免疫相关不良事件 (IRAE). 结果显示,平均无进展生存时间超过1.7年.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
临床研究临床研究

背景情况:

帕西菲克试验确定了第三阶段非小细胞肺癌 (NSCLC) 的辅助剂杜瓦卢马布化学辐射后治疗.
现实世界的数据至关重要,因为临床试验人群可能不反映多样化的患者人口统计和结果.
准确的患者咨询需要了解现实世界的治疗毒性和疗效.

研究的目的:

在第三阶段NSCLC患者中追溯分析辅助药杜瓦卢马布的现实结果和毒性.
为了比较现实世界的数据与关于杜尔瓦卢马布治疗的临床试验结果.
确定常见的免疫相关不良事件 (IRAE) 和其严重程度.

主要方法:

在加拿大第三级癌症中心 (2018年5月 - 2020年10月) 进行了对118名III期NSCLC患者的回顾性分析,这些患者在化学放射治疗后接受了杜尔瓦卢马布治疗.
数据收集包括患者人口统计,治疗特点,无进展生存率 (PFS),总生存率 (OS) 和IRAEs.
毒性分析使用描述性统计数据;使用卡普兰-梅尔法估计了PFS和OS.

主要成果:

观察到总体毒性率为64.4%,其中21%的人经历了3级+IRAE.
最常见的IRAE是肺炎 (40%),皮疹 (18%) 和甲状腺功能障碍 (15%).
估计PFS和OS的中位数分别为> 1.7年和> 2.7年. FEV1和DLCO没有预测肺炎.

结论:

现实世界辅助杜尔瓦卢马布治疗第三阶段NSCLC显示出显著的毒性概况,符合但需要仔细的患者咨询.
免疫相关的不良事件,特别是肺炎,很常见,需要谨慎监测.
观察到的PFS和OS中位数表明在现实环境中有效性持续,支持其在第三阶段NSCLC管理中的作用.

关键词:

达尔瓦卢马布 (Durvalumab) 是一种耐药的药物.免疫疗法免疫疗法其他非小细胞肺癌.肺炎是一种肺炎.第三阶段的肺癌.

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...